Psoriasis Treatment Market Outlook
According to the research reports by MRFR, the global psoriasis treatment market is likely to cross a market size of over USD 13.1 billion in 2025 while recording a healthy CAGR of over 7.3% during the review timeframe.
Psoriasis is a chronic inflammatory skin condition that frequently links with our systematic manifestation. The global psoriasis treatment market has witnessed massive growth over recent years owing to the factors such as various developments of advanced technologies, the green prevalence of psoriasis, increasing awareness for the treatment, and the growing research and development for the treatment. However, the market’s growth is likely to be hampered by the high costs involved in the treatment. Nevertheless, the growing occurrence of this disease across the globe is likely to offer lucrative opportunities over the assessment timeframe.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2769
Psoriasis Treatment Market Segment Analysis
The global psoriasis treatment market is bifurcated into several segments based on treatment, drug class, and region.
Based on the drug class, the global market for psoriasis treatment is divided into vitamin D analogs, interleukin inhibitors, and tumor necrosis factor inhibitors.
The global psoriasis treatment market is split into biologics, systematic, and topical based on the treatment.
Psoriasis Treatment Market Regional Analysis
The global psoriasis treatment market is studied across five major regions, including the Middle East & Africa, North America, South America, Europe, and Asia-Pacific.
As per the MRFR research reports, the North American region is likely to secure the top position in the psoriasis treatment market due to the rising number of global market trends of psoriasis treatment. Furthermore, the growth of the regional market is being driven by an increasing prevalence of psoriasis, the presence of major manufacturers, and growing awareness growth among people. As per the recent survey, approximately 8 million Americans have psoriasis.
In 2018, the European region secured the second position in the psoriasis treatment market across the globe. The regional market will likely record the fastest growth rate over the assessment timeframe. The regional market’s growth is attributed to the prominent market players, the growing participation of major market leaders, and the growing senior population.
The Middle East & African regional psoriasis treatment will record the slowest growth rate over the review timeframe. This is because of less awareness among the people in Africa and the low economic developments across the region.
Psoriasis Treatment Market Competitive Analysis
The global market for psoriasis treatment has an intensely competitive landscape with a wide number of players spread worldwide. The players in the market are adopting several new strategies such as product developments, mergers, acquisitions, and partnerships to strengthen their global market footprint. The list of prominent players in the psoriasis treatment market includes names such as Eli Lilly and Company, AbbVie (US), Pfizer Inc (US), Celgene Corporation (US), UCB (Belgium), Amgen (US), Merck and Co. Inc (US), Johnson & Johnson (US), AstraZeneca (UK), Novartis International AG (Switzerland), and many others.
WellDyne and Mindera Health™ have announced the signing of a definitive agreement to enhance the management of psoriasis patients with average to severe disease using Mind.Px™, a proprietary dermal biomarker patch platform, predicts the proper biologic drug class before treatment.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769
a privately-held, clinical-stage, multi-asset biotechnology company targeted on immunology and infectious diseases, UNION therapeutics A/S, disclosed that the first patient had been registered in a Phase 2b dose-ranging study, IASOS. The study examines the efficacy and safety of oral orismilast in patients ranging from moderate to severe psoriasis.
secukinumab has received approval from the US FDA for patients aged two years or older with active juvenile psoriatic arthritis (JPsA) and individuals aged four years or older with active enthesitis-related arthritis (ERA). It is the first biologic designated for ERA and the first and only biologic treatment for both PsA and ERA in pediatric patients in the United States.
Browse Related Reports at:
Global Veterinary Software Market Research Report—Forecast till 2027
Computer Vision in Healthcare Market Research Report—Forecast till 2027
Membrane Chromatography Market Research Report – Forecast till 2027
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 628 258 0071(US)
+44 2035 002 764(UK)